Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 79

1.

Pembrolizumab in Relapsed and Refractory Mycosis Fungoides and Sézary Syndrome: A Multicenter Phase II Study.

Khodadoust MS, Rook AH, Porcu P, Foss F, Moskowitz AJ, Shustov A, Shanbhag S, Sokol L, Fling SP, Ramchurren N, Pierce R, Davis A, Shine R, Li S, Fong S, Kim J, Yang Y, Blumenschein WM, Yearley JH, Das B, Patidar R, Datta V, Cantu E, McCutcheon JN, Karlovich C, Williams PM, Subrahmanyam PB, Maecker HT, Horwitz SM, Sharon E, Kohrt HE, Cheever MA, Kim YH.

J Clin Oncol. 2019 Sep 18:JCO1901056. doi: 10.1200/JCO.19.01056. [Epub ahead of print]

PMID:
31532724
2.

Targeting CD137 enhances the efficacy of cetuximab.

Kohrt HE, Colevas AD, Houot R, Weiskopf K, Goldstein MJ, Lund P, Mueller A, Sagiv-Barfi I, Marabelle A, Lira R, Troutner E, Richards L, Rajapaska A, Hebb J, Chester C, Waller E, Ostashko A, Weng WK, Chen L, Czerwinski D, Fu YX, Sunwoo J, Levy R.

J Clin Invest. 2019 Jun 3;129(6):2595. doi: 10.1172/JCI129689. Epub 2019 Jun 3. No abstract available.

3.

Stimulation of natural killer cells with a CD137-specific antibody enhances trastuzumab efficacy in xenotransplant models of breast cancer.

Kohrt HE, Houot R, Weiskopf K, Goldstein MJ, Scheeren F, Czerwinski D, Colevas AD, Weng WK, Clarke MF, Carlson RW, Stockdale FE, Mollick JA, Chen L, Levy R.

J Clin Invest. 2019 Jun 3;129(6):2595. doi: 10.1172/JCI129688. Epub 2019 Jun 3. No abstract available.

4.

A First-in-Human Phase I Study of Subcutaneous Outpatient Recombinant Human IL15 (rhIL15) in Adults with Advanced Solid Tumors.

Miller JS, Morishima C, McNeel DG, Patel MR, Kohrt HEK, Thompson JA, Sondel PM, Wakelee HA, Disis ML, Kaiser JC, Cheever MA, Streicher H, Creekmore SP, Waldmann TA, Conlon KC.

Clin Cancer Res. 2018 Apr 1;24(7):1525-1535. doi: 10.1158/1078-0432.CCR-17-2451. Epub 2017 Dec 4.

5.

Antigen presentation profiling reveals recognition of lymphoma immunoglobulin neoantigens.

Khodadoust MS, Olsson N, Wagar LE, Haabeth OA, Chen B, Swaminathan K, Rawson K, Liu CL, Steiner D, Lund P, Rao S, Zhang L, Marceau C, Stehr H, Newman AM, Czerwinski DK, Carlton VE, Moorhead M, Faham M, Kohrt HE, Carette J, Green MR, Davis MM, Levy R, Elias JE, Alizadeh AA.

Nature. 2017 Mar 30;543(7647):723-727. doi: 10.1038/nature21433. Epub 2017 Mar 22.

6.

Distinct patterns of B-cell receptor signaling in non-Hodgkin lymphomas identified by single-cell profiling.

Myklebust JH, Brody J, Kohrt HE, Kolstad A, Czerwinski DK, Wälchli S, Green MR, Trøen G, Liestøl K, Beiske K, Houot R, Delabie J, Alizadeh AA, Irish JM, Levy R.

Blood. 2017 Feb 9;129(6):759-770. doi: 10.1182/blood-2016-05-718494. Epub 2016 Dec 23.

7.

Characterizing CD137 upregulation on NK cells in patients receiving monoclonal antibody therapy.

Makkouk A, Sundaram V, Chester C, Chang S, Colevas AD, Sunwoo JB, Maecker H, Desai M, Kohrt HE.

Ann Oncol. 2017 Feb 1;28(2):415-420. doi: 10.1093/annonc/mdw570.

8.

Blood Stem Cell Activity Is Arrested by Th1-Mediated Injury Preventing Engraftment following Nonmyeloablative Conditioning.

Müller AM, Florek M, Kohrt HE, Küpper NJ, Filatenkov A, Linderman JA, Hadeiba H, Negrin RS, Shizuru JA.

J Immunol. 2016 Nov 15;197(10):4151-4162. Epub 2016 Oct 10.

9.

Anti-CD137 enhances anti-CD20 therapy of systemic B-cell lymphoma with altered immune homeostasis but negligible toxicity.

Souza-Fonseca-Guimaraes F, Blake SJ, Makkouk A, Chester C, Kohrt HE, Smyth MJ.

Oncoimmunology. 2016 Jun 30;5(7):e1192740. doi: 10.1080/2162402X.2016.1192740. eCollection 2016 Jul.

10.

Assessing Immune-Related Adverse Events of Efficacious Combination Immunotherapies in Preclinical Models of Cancer.

Liu J, Blake SJ, Harjunpää H, Fairfax KA, Yong MC, Allen S, Kohrt HE, Takeda K, Smyth MJ, Teng MW.

Cancer Res. 2016 Sep 15;76(18):5288-301. doi: 10.1158/0008-5472.CAN-16-0194. Epub 2016 Aug 8.

11.

Strategic Combinations: The Future of Oncolytic Virotherapy with Reovirus.

Zhao X, Chester C, Rajasekaran N, He Z, Kohrt HE.

Mol Cancer Ther. 2016 May;15(5):767-73. doi: 10.1158/1535-7163.MCT-15-0695. Epub 2016 Apr 14. Review.

12.

PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma.

Nghiem PT, Bhatia S, Lipson EJ, Kudchadkar RR, Miller NJ, Annamalai L, Berry S, Chartash EK, Daud A, Fling SP, Friedlander PA, Kluger HM, Kohrt HE, Lundgren L, Margolin K, Mitchell A, Olencki T, Pardoll DM, Reddy SA, Shantha EM, Sharfman WH, Sharon E, Shemanski LR, Shinohara MM, Sunshine JC, Taube JM, Thompson JA, Townson SM, Yearley JH, Topalian SL, Cheever MA.

N Engl J Med. 2016 Jun 30;374(26):2542-52. doi: 10.1056/NEJMoa1603702. Epub 2016 Apr 19.

13.

4-1BB agonism: adding the accelerator to cancer immunotherapy.

Chester C, Ambulkar S, Kohrt HE.

Cancer Immunol Immunother. 2016 Oct;65(10):1243-8. doi: 10.1007/s00262-016-1829-2. Epub 2016 Mar 31. Review.

14.

Immunodynamics: a cancer immunotherapy trials network review of immune monitoring in immuno-oncology clinical trials.

Kohrt HE, Tumeh PC, Benson D, Bhardwaj N, Brody J, Formenti S, Fox BA, Galon J, June CH, Kalos M, Kirsch I, Kleen T, Kroemer G, Lanier L, Levy R, Lyerly HK, Maecker H, Marabelle A, Melenhorst J, Miller J, Melero I, Odunsi K, Palucka K, Peoples G, Ribas A, Robins H, Robinson W, Serafini T, Sondel P, Vivier E, Weber J, Wolchok J, Zitvogel L, Disis ML, Cheever MA; Cancer Immunotherapy Trials Network (CITN).

J Immunother Cancer. 2016 Mar 15;4:15. doi: 10.1186/s40425-016-0118-0. eCollection 2016. Review.

15.

Harnessing the innate immune system to treat cancer: enhancement of antibody-dependent cellular cytotoxicity with anti-CD137 Ab.

Yonezawa A, Chester C, Rajasekaran N, Kohrt HE.

Chin Clin Oncol. 2016 Feb;5(1):5. doi: 10.3978/j.issn.2304-3865.2016.02.05. Review. No abstract available.

16.

CD44+ Cells in Head and Neck Squamous Cell Carcinoma Suppress T-Cell-Mediated Immunity by Selective Constitutive and Inducible Expression of PD-L1.

Lee Y, Shin JH, Longmire M, Wang H, Kohrt HE, Chang HY, Sunwoo JB.

Clin Cancer Res. 2016 Jul 15;22(14):3571-81. doi: 10.1158/1078-0432.CCR-15-2665. Epub 2016 Feb 10.

17.

In situ vaccination for the treatment of cancer.

Hammerich L, Bhardwaj N, Kohrt HE, Brody JD.

Immunotherapy. 2016;8(3):315-30. doi: 10.2217/imt.15.120. Epub 2016 Feb 9. Review.

PMID:
26860335
18.

Rationale for anti-CD137 cancer immunotherapy.

Makkouk A, Chester C, Kohrt HE.

Eur J Cancer. 2016 Feb;54:112-119. doi: 10.1016/j.ejca.2015.09.026. Epub 2016 Jan 2. Review.

PMID:
26751393
19.

Natural Killer Cell Immunomodulation: Targeting Activating, Inhibitory, and Co-stimulatory Receptor Signaling for Cancer Immunotherapy.

Chester C, Fritsch K, Kohrt HE.

Front Immunol. 2015 Dec 2;6:601. doi: 10.3389/fimmu.2015.00601. eCollection 2015. Review.

20.

Scientific Significance of Clinically Insignificant FcγRIIIa-V158F Polymorphism.

Cartron G, Houot R, Kohrt HE.

Clin Cancer Res. 2016 Feb 15;22(4):787-9. doi: 10.1158/1078-0432.CCR-15-2777. Epub 2015 Dec 18.

21.

A quantitative analysis of therapeutic cancer vaccines in phase 2 or phase 3 trial.

Tan AC, Goubier A, Kohrt HE.

J Immunother Cancer. 2015 Nov 17;3:48. doi: 10.1186/s40425-015-0093-x. eCollection 2015. Review.

22.

Critical issues in cancer vaccine trial design.

Clifton GT, Kohrt HE, Peoples GE.

Vaccine. 2015 Dec 16;33(51):7386-7392. doi: 10.1016/j.vaccine.2015.09.019. Epub 2015 Sep 19. Review.

PMID:
26392010
23.

Allogeneic hematopoietic cell transplantation after failed autologous transplant for lymphoma using TLI and anti-thymocyte globulin conditioning.

Rezvani AR, Kanate AS, Efron B, Chhabra S, Kohrt HE, Shizuru JA, Laport GG, Miklos DB, Benjamin JE, Johnston LJ, Arai S, Weng WK, Negrin RS, Strober S, Lowsky R.

Bone Marrow Transplant. 2015 Oct;50(10):1286-92. doi: 10.1038/bmt.2015.149. Epub 2015 Jul 6.

24.

In-situ tumor vaccination: Bringing the fight to the tumor.

Pierce RH, Campbell JS, Pai SI, Brody JD, Kohrt HE.

Hum Vaccin Immunother. 2015;11(8):1901-9. doi: 10.1080/21645515.2015.1049779. Review.

25.

Boosting Cancer Immunotherapy with Anti-CD137 Antibody Therapy.

Yonezawa A, Dutt S, Chester C, Kim J, Kohrt HE.

Clin Cancer Res. 2015 Jul 15;21(14):3113-20. doi: 10.1158/1078-0432.CCR-15-0263. Epub 2015 Apr 23. Review.

26.

Therapeutic antitumor immunity by checkpoint blockade is enhanced by ibrutinib, an inhibitor of both BTK and ITK.

Sagiv-Barfi I, Kohrt HE, Czerwinski DK, Ng PP, Chang BY, Levy R.

Proc Natl Acad Sci U S A. 2015 Mar 3;112(9):E966-72. doi: 10.1073/pnas.1500712112. Epub 2015 Feb 17.

27.

Ibrutinib enhances the antitumor immune response induced by intratumoral injection of a TLR9 ligand in mouse lymphoma.

Sagiv-Barfi I, Kohrt HE, Burckhardt L, Czerwinski DK, Levy R.

Blood. 2015 Mar 26;125(13):2079-86. doi: 10.1182/blood-2014-08-593137. Epub 2015 Feb 6.

28.

Dual antibody therapy to harness the innate anti-tumor immune response to enhance antibody targeting of tumors.

Chester C, Marabelle A, Houot R, Kohrt HE.

Curr Opin Immunol. 2015 Apr;33:1-8. doi: 10.1016/j.coi.2014.12.010. Epub 2015 Jan 7. Review.

PMID:
25576932
29.

Enhancement of antibody-dependent cell mediated cytotoxicity: a new era in cancer treatment.

Rajasekaran N, Chester C, Yonezawa A, Zhao X, Kohrt HE.

Immunotargets Ther. 2015 May 15;4:91-100. doi: 10.2147/ITT.S61292. eCollection 2015. Review.

30.

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients.

Herbst RS, Soria JC, Kowanetz M, Fine GD, Hamid O, Gordon MS, Sosman JA, McDermott DF, Powderly JD, Gettinger SN, Kohrt HE, Horn L, Lawrence DP, Rost S, Leabman M, Xiao Y, Mokatrin A, Koeppen H, Hegde PS, Mellman I, Chen DS, Hodi FS.

Nature. 2014 Nov 27;515(7528):563-7. doi: 10.1038/nature14011.

31.

Diffuse high intensity PD-L1 staining in thymic epithelial tumors.

Padda SK, Riess JW, Schwartz EJ, Tian L, Kohrt HE, Neal JW, West RB, Wakelee HA.

J Thorac Oncol. 2015 Mar;10(3):500-8. doi: 10.1097/JTO.0000000000000429.

32.

Child abuse, disruptive behavior disorders, depression, and salivary cortisol levels among institutionalized and community-residing boys in Mongolia.

Kohrt BA, Hruschka DJ, Kohrt HE, Carrion VG, Waldman ID, Worthman CM.

Asia Pac Psychiatry. 2015 Mar;7(1):7-19. doi: 10.1111/appy.12141. Epub 2014 Jun 3.

PMID:
24890783
33.

Targeting CD137 enhances the efficacy of cetuximab.

Kohrt HE, Colevas AD, Houot R, Weiskopf K, Goldstein MJ, Lund P, Mueller A, Sagiv-Barfi I, Marabelle A, Lira R, Troutner E, Richards L, Rajapaska A, Hebb J, Chester C, Waller E, Ostashko A, Weng WK, Chen L, Czerwinski D, Fu YX, Sunwoo J, Levy R.

J Clin Invest. 2014 Jun;124(6):2668-82. doi: 10.1172/JCI73014. Epub 2014 May 16. Retraction in: J Clin Invest. 2019 Jun 3;129(6):2595.

34.

Ibrutinib antagonizes rituximab-dependent NK cell-mediated cytotoxicity.

Kohrt HE, Sagiv-Barfi I, Rafiq S, Herman SE, Butchar JP, Cheney C, Zhang X, Buggy JJ, Muthusamy N, Levy R, Johnson AJ, Byrd JC.

Blood. 2014 Mar 20;123(12):1957-60. doi: 10.1182/blood-2014-01-547869. No abstract available.

35.

Total lymphoid irradiation-antithymocyte globulin conditioning and allogeneic transplantation for patients with myelodysplastic syndromes and myeloproliferative neoplasms.

Benjamin J, Chhabra S, Kohrt HE, Lavori P, Laport GG, Arai S, Johnston L, Miklos DB, Shizuru JA, Weng WK, Negrin RS, Lowsky R.

Biol Blood Marrow Transplant. 2014 Jun;20(6):837-43. doi: 10.1016/j.bbmt.2014.02.023. Epub 2014 Mar 7.

36.

Donor hematopoiesis in mice following total lymphoid irradiation requires host T-regulatory cells for durable engraftment.

Müller AM, Poyser J, Küpper NJ, Burnett C, Ko RM, Kohrt HE, Florek M, Zhang P, Negrin RS, Shizuru JA.

Blood. 2014 May 1;123(18):2882-92. doi: 10.1182/blood-2013-10-530212. Epub 2014 Mar 3.

37.

Inhibition of CXCR7 extends survival following irradiation of brain tumours in mice and rats.

Walters MJ, Ebsworth K, Berahovich RD, Penfold ME, Liu SC, Al Omran R, Kioi M, Chernikova SB, Tseng D, Mulkearns-Hubert EE, Sinyuk M, Ransohoff RM, Lathia JD, Karamchandani J, Kohrt HE, Zhang P, Powers JP, Jaen JC, Schall TJ, Merchant M, Recht L, Brown JM.

Br J Cancer. 2014 Mar 4;110(5):1179-88. doi: 10.1038/bjc.2013.830. Epub 2014 Jan 14.

38.

Anti-KIR antibody enhancement of anti-lymphoma activity of natural killer cells as monotherapy and in combination with anti-CD20 antibodies.

Kohrt HE, Thielens A, Marabelle A, Sagiv-Barfi I, Sola C, Chanuc F, Fuseri N, Bonnafous C, Czerwinski D, Rajapaksa A, Waller E, Ugolini S, Vivier E, Romagné F, Levy R, Bléry M, André P.

Blood. 2014 Jan 30;123(5):678-86. doi: 10.1182/blood-2013-08-519199. Epub 2013 Dec 10.

39.

Modulation of natural killer cell antitumor activity by the aryl hydrocarbon receptor.

Shin JH, Zhang L, Murillo-Sauca O, Kim J, Kohrt HE, Bui JD, Sunwoo JB.

Proc Natl Acad Sci U S A. 2013 Jul 23;110(30):12391-6. doi: 10.1073/pnas.1302856110. Epub 2013 Jul 8.

40.

Identification of gene microarray expression profiles in patients with chronic graft-versus-host disease following allogeneic hematopoietic cell transplantation.

Kohrt HE, Tian L, Li L, Alizadeh AA, Hsieh S, Tibshirani RJ, Strober S, Sarwal M, Lowsky R.

Clin Immunol. 2013 Jul;148(1):124-35. doi: 10.1016/j.clim.2013.04.013. Epub 2013 May 1.

PMID:
23685278
41.

High PD-1 expression and suppressed cytokine signaling distinguish T cells infiltrating follicular lymphoma tumors from peripheral T cells.

Myklebust JH, Irish JM, Brody J, Czerwinski DK, Houot R, Kohrt HE, Timmerman J, Said J, Green MR, Delabie J, Kolstad A, Alizadeh AA, Levy R.

Blood. 2013 Feb 21;121(8):1367-76. doi: 10.1182/blood-2012-04-421826. Epub 2013 Jan 7.

42.

Cancer vaccines and T cell therapy.

Rezvani K, Brody JD, Kohrt HE, Logan AC, Advani R, Czerwinski DK, Weng WK, Negrin RS, Carlton V, Faham M, Levy R, Barrett J.

Biol Blood Marrow Transplant. 2013 Jan;19(1 Suppl):S97-S101. doi: 10.1016/j.bbmt.2012.09.020. Epub 2012 Oct 3. Review. No abstract available.

43.

The chemoattractant chemerin suppresses melanoma by recruiting natural killer cell antitumor defenses.

Pachynski RK, Zabel BA, Kohrt HE, Tejeda NM, Monnier J, Swanson CD, Holzer AK, Gentles AJ, Sperinde GV, Edalati A, Hadeiba HA, Alizadeh AA, Butcher EC.

J Exp Med. 2012 Jul 30;209(8):1427-35. doi: 10.1084/jem.20112124. Epub 2012 Jul 2.

44.

2-Hydroxyglutarate in IDH mutant acute myeloid leukemia: predicting patient responses, minimal residual disease and correlations with methylcytosine and hydroxymethylcytosine levels.

Pollyea DA, Kohrt HE, Zhang B, Zehnder J, Schenkein D, Fantin V, Straley K, Vasanthakumar A, Abdel-Wahab O, Levine R, Godley LA, Medeiros BC.

Leuk Lymphoma. 2013 Feb;54(2):408-10. doi: 10.3109/10428194.2012.701009. Epub 2012 Jul 9. No abstract available.

45.

Combination strategies to enhance antitumor ADCC.

Kohrt HE, Houot R, Marabelle A, Cho HJ, Osman K, Goldstein M, Levy R, Brody J.

Immunotherapy. 2012 May;4(5):511-27. doi: 10.2217/imt.12.38. Review.

46.

Rapid development of exhaustion and down-regulation of eomesodermin limit the antitumor activity of adoptively transferred murine natural killer cells.

Gill S, Vasey AE, De Souza A, Baker J, Smith AT, Kohrt HE, Florek M, Gibbs KD Jr, Tate K, Ritchie DS, Negrin RS.

Blood. 2012 Jun 14;119(24):5758-68. doi: 10.1182/blood-2012-03-415364. Epub 2012 Apr 27.

47.

Co-transplantation of pure blood stem cells with antigen-specific but not bulk T cells augments functional immunity.

Müller AM, Shashidhar S, Küpper NJ, Kohrt HE, Florek M, Negrin RS, Brown JM, Shizuru JA.

Proc Natl Acad Sci U S A. 2012 Apr 10;109(15):5820-5. doi: 10.1073/pnas.1120237109. Epub 2012 Mar 22.

48.

Stimulation of natural killer cells with a CD137-specific antibody enhances trastuzumab efficacy in xenotransplant models of breast cancer.

Kohrt HE, Houot R, Weiskopf K, Goldstein MJ, Scheeren F, Czerwinski D, Colevas AD, Weng WK, Clarke MF, Carlson RW, Stockdale FE, Mollick JA, Chen L, Levy R.

J Clin Invest. 2012 Mar;122(3):1066-75. doi: 10.1172/JCI61226. Epub 2012 Feb 13. Retraction in: J Clin Invest. 2019 Jun 3;129(6):2595.

49.

What happened to the concept of the physician-scientist?

Goldstein MJ, Kohrt HE.

Acad Med. 2012 Feb;87(2):132-3. doi: 10.1097/ACM.0b013e31823f0eeb. No abstract available.

PMID:
22273607
50.

Adoptive cell therapy for lymphoma with CD4 T cells depleted of CD137-expressing regulatory T cells.

Goldstein MJ, Kohrt HE, Houot R, Varghese B, Lin JT, Swanson E, Levy R.

Cancer Res. 2012 Mar 1;72(5):1239-47. doi: 10.1158/0008-5472.CAN-11-3375. Epub 2012 Jan 9.

Supplemental Content

Loading ...
Support Center